+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market- Product Image
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market- Product Image
New

Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

  • PDF Icon

    Report

  • 155 Pages
  • July 2025
  • Region: Global
  • BCC Research
  • ID: 6111116
Description Jump to:
The global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to 2030.

IBS and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients’ quality of life and achieve clinical remission for the longest period possible.

The key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products.

Report Scope

The report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class.
  • By symptom type, IBS therapeutics include IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed symptoms (IBS-M).
  • By drug class, IBS therapeutics include guanylate cyclase-C agonists, antibiotics, laxatives, antispasmodics and others.
The IBD therapeutics segment is further segmented based on type and drug class.
  • By type, IBD therapeutics include ulcerative colitis and Crohn’s disease.
  • By drug class, therapeutics for IBD include interleukin inhibitors, integrin antagonists, TNF inhibitors, JAK (Janus kinases) inhibitors, and others
The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also included.

The scope does not cover alternative therapies for IBS and IBD, such as herbal medicine, dietary supplements and behavioral therapies.

The report includes:

  • 142 data tables and 54 additional tables
  • Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics
  • Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
  • Estimates of the market’s size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors
  • Insights derived from Porter’s Five Forces model, as well as global supply chain analysis
  • Patent analysis, featuring key granted and published patents
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Profiles of the leading companies, includingAbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion
Chapter 2 Market Overview
  • Overview
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome
  • Porter's Five Forces Analysis in the Ibs and Ibd Therapeutics Market
  • Potential of New Entrants (Low to Moderate)
  • Bargaining Power of Suppliers (Low)
  • Bargaining Power of Buyers (High)
  • Threat of Substitute Products (Moderate)
  • Industry Rivalry (High)
  • Impact of U.S. Tariffs
  • Macroeconomic Factor Analysis
  • Population Demographics and Aging Populations
  • Government Policies on Drug Prices
Chapter 3 Market Dynamics
  • Market Dynamics
  • Market Drivers
  • Rising Prevalence of Gastrointestinal Disorders
  • Increasing Entry of Biologics and Biosimilars
  • Market Restraints
  • Side Effects and Ceiling Impact of Biologics
  • Overlap with Other Gi Disorders
  • Use of Alternative Treatment Approaches
  • Market Opportunities
  • Self-Administered Drugs
  • Personalized Therapies
Chapter 4 Regulatory Landscape
  • Regulatory Aspects of Ibs and Ibd Therapeutics
  • The U.S.
  • European Union
  • Asia-Pacific
Chapter 5 Emerging Technologies and Pipeline Analysis
  • Key Takeaways
  • Emerging Technologies
  • Novel Target-based Small-Molecule Drugs
  • Microbiome-based Therapeutics
  • Advanced Combination Treatments
  • AI for Drug Discovery
  • Pipeline Analysis
Chapter 6 Market Segmentation Analysis
  • Segmentation Breakdown
  • Market Analysis by Disease
  • Key Takeaways
  • Irritable Bowel Syndrome
  • Inflammatory Bowel Disease
  • Market Analysis by Drug Class
  • Key Takeaways
  • Irritable Bowel Syndrome
  • Inflammatory Bowel Disease
  • Geographic Breakdown
  • Market Analysis by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa
Chapter 7 Competitive Intelligence
  • Key Takeaways
  • Industry Structure
  • Company Share Analysis of the Ibd Therapeutics Market
  • Competitive Share Analysis of the Ibs Therapeutics Market
  • Strategic Analysis
Chapter 8 Sustainability in the Ibs and Ibd Market: An ESG Perspective
  • Introduction to ESG
  • ESG Risk Ratings
  • Conclusion
Chapter 9 Appendix
  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bayer AG
  • Biogen
  • Bristol-Myers Squibb Co.
  • Gilead Sciences Inc.
  • Ironwood
  • Johnson & Johnson Services Inc.
  • Lilly
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • Ucb SA
  • Emerging Start-Ups/ Market Disruptors
List of Tables
Summary Table: Global IBS and IBD Therapeutics Market, by Region, Through 2030
Table 1: Differences Between IBD and IBS
Table 2: List of Active Clinical Trials in Phase III, 2025
Table 3: List of Active Clinical Trials in Phase II, 2025
Table 4: List of Active Clinical Trials in Phase I, 2025
Table 5: Global IBS and IBD Therapeutics Market, by Disease, Through 2030
Table 6: Global IBS Therapeutics Market, by Region, Through 2030
Table 7: Global IBS Therapeutics Market, by Symptom Type, Through 2030
Table 8: Global IBS-D Therapeutics Market, by Region, Through 2030
Table 9: Global IBS-C Therapeutics Market, by Region, Through 2030
Table 10: Global IBS-M Therapeutics Market, by Region, Through 2030
Table 11: Inflammatory Bowel Disease Types
Table 12: Global IBD Therapeutics Market, by Region, Through 2030
Table 13: Global IBD Therapeutics Market, by Type, Through 2030
Table 14: Global UC Therapeutics Market, by Region, Through 2030
Table 15: Global CD Therapeutics Market, by Region, Through 2030
Table 16: Global IBS Therapeutics Market, by Drug Class, Through 2030
Table 17: Global IBS Guanylate Cyclase-C Agonists Market, by Region, Through 2030
Table 18: Global IBS Antibiotics Market, by Region, Through 2030
Table 19: Global IBS Laxatives Market, by Region, Through 2030
Table 20: Global IBS Antispasmodics Market, by Region, Through 2030
Table 21: Global Other IBS Drug Class Therapeutics Market, by Region, Through 2030
Table 22: Global IBD Therapeutics Market, by Drug Class, Through 2030
Table 23: Global IBD Interleukin Inhibitors Market, by Region, Through 2030
Table 24: Global IBD Integrin Antagonists Market, by Region, Through 2030
Table 25: Global IBD TNF Blockers Market, by Region, Through 2030
Table 26: Global IBD JAK Inhibitors Market, by Region, Through 2030
Table 27: Global Other IBD Drug Class Therapeutics Market, by Region, Through 2030
Table 28: Global IBS and IBD Therapeutics Market, by Region, Through 2030
Table 29: North American IBS and IBD Therapeutics Market, by Country, Through 2030
Table 30: North American IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 31: North American IBS Therapeutics Market, by Symptom Type, Through 2030
Table 32: North American IBS Therapeutics Market, by Drug Class, Through 2030
Table 33: North American IBD Therapeutics Market, by Type, Through 2030
Table 34: North American IBD Therapeutics Market, by Drug Class, Through 2030
Table 35: U.S. IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 36: U.S. IBS Therapeutics Market, by Symptom Type, Through 2030
Table 37: U.S. IBS Therapeutics Market, by Drug Class, Through 2030
Table 38: U.S. IBD Therapeutics Market, by Type, Through 2030
Table 39: U.S. IBD Therapeutics Market, by Drug Class, Through 2030
Table 40: Canadian IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 41: Canadian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 42: Canadian IBS Therapeutics Market, by Drug Class, Through 2030
Table 43: Canadian IBD Therapeutics Market, by Type, Through 2030
Table 44: Canadian IBD Therapeutics Market, by Drug Class, Through 2030
Table 45: Mexican IBS and IBD Market, by Disease Type, Through 2030
Table 46: Mexican IBS Therapeutics Market, by Symptom Type, Through 2030
Table 47: Mexican IBS Therapeutics Market, by Drug Class, Through 2030
Table 48: Mexican IBD Therapeutics Market, by Type, Through 2030
Table 49: Mexican IBD Therapeutics Market, by Drug Class, Through 2030
Table 50: European IBS and IBD Therapeutics Market, by Country, Through 2030
Table 51: European IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 52: European IBS Therapeutics Market, by Symptom Type, Through 2030
Table 53: European IBS Therapeutics Market, by Drug Class, Through 2030
Table 54: European IBD Therapeutics Market, by Type, Through 2030
Table 55: European IBD Therapeutics Market, by Drug Class, Through 2030
Table 56: U.K. IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 57: U.K. IBS Therapeutics Market, by Symptom Type, Through 2030
Table 58: U.K. IBS Therapeutics Market, by Drug Class, Through 2030
Table 59: U.K. IBD Therapeutics Market, by Type, Through 2030
Table 60: U.K. IBD Therapeutics Market, by Drug Class, Through 2030
Table 61: German IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 62: German IBS Therapeutics Market, by Symptom Type, Through 2030
Table 63: German IBS Therapeutics Market, by Drug Class, Through 2030
Table 64: German IBD Therapeutics Market, by Type, Through 2030
Table 65: German IBD Therapeutics Market, by Drug Class, Through 2030
Table 66: French IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 67: French IBS Therapeutics Market, by Symptom Type, Through 2030
Table 68: French IBS Therapeutics Market, by Drug Class, Through 2030
Table 69: French IBD Therapeutics Market, by Type, Through 2030
Table 70: French IBD Therapeutics Market, by Drug Class, Through 2030
Table 71: Italian IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 72: Italian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 73: Italian IBS Therapeutics Market, by Drug Class, Through 2030
Table 74: Italian IBD Therapeutics Market, by Type, Through 2030
Table 75: Italian IBD Therapeutics Market, by Drug Class, Through 2030
Table 76: Spanish IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 77: Spanish IBS Therapeutics Market, by Symptom Type, Through 2030
Table 78: Spanish IBS Therapeutics Market, by Drug Class, Through 2030
Table 79: Spanish IBD Therapeutics Market, by Type, Through 2030
Table 80: Spanish IBD Therapeutics Market, by Drug Class, Through 2030
Table 81: Rest of Europe IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 82: Rest of Europe IBS Therapeutics Market, by Symptom Type, Through 2030
Table 83: Rest of Europe IBS Therapeutics Market, by Drug Class, Through 2030
Table 84: Rest of Europe IBD Therapeutics Market, by Type, Through 2030
Table 85: Rest of Europe IBD Therapeutics Market, by Drug Class, Through 2030
Table 86: Asia-Pacific IBS and IBD Therapeutics Market, by Country, Through 2030
Table 87: Asia-Pacific IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 88: Asia-Pacific IBS Therapeutics Market, by Symptom Type, Through 2030
Table 89: Asia-Pacific IBS Therapeutics Market, by Drug Class, Through 2030
Table 90: Asia-Pacific IBD Therapeutics Market, by Type, Through 2030
Table 91: Asia-Pacific IBD Therapeutics Market, by Drug Class, Through 2030
Table 92: Chinese IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 93: Chinese IBS Therapeutics Market, by Symptom Type, Through 2030
Table 94: Chinese IBS Therapeutics Market, by Drug Class, Through 2030
Table 95: Chinese IBD Therapeutics Market, by Type, Through 2030
Table 96: Chinese IBD Therapeutics Market, by Drug Class, Through 2030
Table 97: Australian IBS and IBD Market, by Disease Type, Through 2030
Table 98: Australian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 99: Australian IBS Therapeutics Market, by Drug Class, Through 2030
Table 100: Australian IBD Therapeutics Market, by Type, Through 2030
Table 101: Australian IBD Therapeutics Market, by Drug Class, Through 2030
Table 102: Japanese IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 103: Japanese IBS Therapeutics Market, by Symptom Type, Through 2030
Table 104: Japanese IBS Therapeutics Market, by Drug Class, Through 2030
Table 105: Japanese IBD Therapeutics Market, by Type, Through 2030
Table 106: Japanese IBD Therapeutics Market, by Drug Class, Through 2030
Table 107: Indian IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 108: Indian IBS Therapeutics Market, by Symptom Type, Through 2030
Table 109: Indian IBS Therapeutics Market, by Drug Class, Through 2030
Table 110: Indian IBD Therapeutics Market, by Type, Through 2030
Table 111: Indian IBD Therapeutics Market, by Drug Class, Through 2030
Table 112: South Korean IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 113: South Korean IBS Therapeutics Market, by Symptom Type, Through 2030
Table 114: South Korean IBS Therapeutics Market, by Drug Class, Through 2030
Table 115: South Korean IBD Therapeutics Market, by Type, Through 2030
Table 116: South Korean IBD Therapeutics Market, by Drug Class, Through 2030
Table 117: Rest of Asia-Pacific IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 118: Rest of Asia-Pacific IBS Therapeutics Market, by Symptom Type, Through 2030
Table 119: Rest of Asia-Pacific IBS Therapeutics Market, by Drug Class, Through 2030
Table 120: Rest of Asia-Pacific IBD Therapeutics Market, by Type, Through 2030
Table 121: Rest of Asia-Pacific IBD Therapeutics Market, by Drug Class, Through 2030
Table 122: South American IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 123: South American IBS Therapeutics Market, by Symptom Type, Through 2030
Table 124: South American IBS Therapeutics Market, by Drug Class, Through 2030
Table 125: South American IBD Therapeutics Market, by Type, Through 2030
Table 126: South American IBD Therapeutics Market, by Drug Class, Through 2030
Table 127: MEA IBS and IBD Therapeutics Market, by Disease Type, Through 2030
Table 128: MEA IBS Therapeutics Market, by Symptom Type, Through 2030
Table 129: MEA IBS Therapeutics Market, by Drug Class, Through 2030
Table 130: MEA IBD Therapeutics Market, by Type, Through 2030
Table 131: MEA IBD Therapeutics Market, by Drug Class, Through 2030
Table 132: Recent Developments in the IBS and IBD Therapeutics Market, 2022-2024
Table 133: ESG Risk Rankings for IBS and IBD Therapeutic Companies, 2025
Table 134: Report Information Sources
Table 135: Abbreviations Used in the Global IBS and IBD Market
Table 136: AbbVie Inc.: Company Snapshot
Table 137: AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 138: AbbVie Inc.: Product Portfolio
Table 139: AbbVie Inc.: News/Key Developments, 2024 and 2023
Table 140: Amgen Inc.: Company Snapshot
Table 141: Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 142: Amgen Inc.: Product Portfolio
Table 143: Amgen Inc.: News/Key Developments, 2022 and 2023
Table 144: AstraZeneca: Company Snapshot
Table 145: AstraZeneca: Financial Performance, FY 2023 and 2024
Table 146: AstraZeneca: Product Portfolio
Table 147: AstraZeneca: News/Recent Developments, 2023
Table 148: Bayer AG: Company Snapshot
Table 149: Bayer AG: Financial Performance, FY 2023 and 2024
Table 150: Bayer AG: Product Portfolio
Table 151: Bayer AG: News/Key Developments, 2024
Table 152: Biogen: Company Snapshot
Table 153: Biogen: Financial Performance, FY 2023 and 2024
Table 154: Biogen: Product Portfolio
Table 155: Biogen: News/Key Developments, 2022
Table 156: Bristol-Myers Squibb Co.: Company Snapshot
Table 157: Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 158: Bristol-Myers Squibb Co.: Product Portfolio
Table 159: Bristol-Myers Squibb Co.: News/Key Developments, 2022-2024
Table 160: Gilead Sciences Inc.: Company Snapshot
Table 161: Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 162: Gilead Sciences Inc.: Product Portfolio
Table 163: Gilead Sciences Inc.: News/Key Developments, 2024
Table 164: Ironwood: Company Snapshot
Table 165: Ironwood: Financial Performance, FY 2023 and 2024
Table 166: Ironwood: Product Portfolio
Table 167: Ironwood: News/Key Developments, 2023
Table 168: Johnson & Johnson Services Inc.: Company Snapshot
Table 169: Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 170: Johnson & Johnson Services Inc.: Product Portfolio
Table 171: Johnson & Johnson Services Inc.: News/Key Developments, 2024
Table 172: Lilly: Company Snapshot
Table 173: Lilly: Financial Performance, FY 2023 and 2024
Table 174: Lilly: Product Portfolio
Table 175: Lilly: News/Key Developments, 2024
Table 176: Merck & Co. Inc.: Company Snapshot
Table 177: Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 178: Merck & Co. Inc.: Product Portfolio
Table 179: Merck & Co. Inc.: News/Key Developments, 2023
Table 180: Pfizer Inc.: Company Snapshot
Table 181: Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 182: Pfizer Inc.: Product Portfolio
Table 183: Pfizer Inc.: News/Key Developments, 2024
Table 184: Sanofi: Company Snapshot
Table 185: Sanofi: Financial Performance, FY 2023 and 2024
Table 186: Sanofi: Product Portfolio
Table 187: Sanofi: News/Key Developments, 2023
Table 188: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 189: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 190: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 191: Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023
Table 192: UCB S.A.: Company Snapshot
Table 193: UCB S.A.: Financial Performance, FY 2023 and 2024
Table 194: UCB S.A.: Product Portfolio
Table 195: List of Few Emerging Startups
List of Figures
Summary Figure: Global IBS and IBD Therapeutics Market Shares, by Region, 2024
Figure 1: Porter’s Five Forces Analysis of the IBS and IBD Therapeutics Industry
Figure 2: Global Market Dynamics of IBS and IBD Therapeutics
Figure 3: Emerging Technologies in the IBS and IBD Therapeutics Market
Figure 4: Global IBS and IBD Therapeutics Market Shares, by Disease, 2024
Figure 5: Global IBS Therapeutics Market Shares, by Symptom Type, 2024
Figure 6: Global IBD Therapeutics Market Shares, by Type, 2024
Figure 7: Global IBS Therapeutics Market Shares, by Drug Class, 2024
Figure 8: Global IBD Therapeutics Market Shares, by Drug Class, 2024
Figure 9: Global IBS and IBD Therapeutics Market Shares, by Region, 2024
Figure 10: North American IBS and IBD Therapeutics Market Shares, by Country, 2024
Figure 11: European IBS and IBD Therapeutics Market Shares, by Country, 2024
Figure 12: Asia-Pacific IBS and IBD Therapeutics Market Shares, by Country, 2024
Figure 13: Company Share Analysis of IBD Therapeutics Market, 2024
Figure 14: Company Share Analysis of IBS Therapeutics Market, 2024
Figure 15: Key ESG Metrics of IBS and IBD Therapeutics Companies
Figure 16: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 17: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 18: Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 19: Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 20: AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 21: AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 22: Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 23: Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 24: Biogen: Revenue Shares, by Business Unit, FY 2024
Figure 25: Biogen: Revenue Shares, by Country/Region, FY 2024
Figure 26: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 27: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 28: Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 29: Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 30: Ironwood: Revenue Shares, by Country/Region, FY 2024
Figure 31: Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 32: Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 33: Lilly: Revenue Shares, by Business Unit, FY 2024
Figure 34: Lilly: Revenue Shares, by Country/Region, FY 2024
Figure 35: Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 36: Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 37: Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 38: Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 39: Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 40: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 41: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 42: UCB S.A.: Revenue Shares, by Business Unit, FY 2024
Figure 43: UCB S.A.: Revenue Shares, by Country/Region, FY 2024

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bayer AG
  • Biogen
  • Bristol-Myers Squibb Co.
  • Gilead Sciences Inc.
  • Ironwood
  • Johnson & Johnson Services Inc.
  • Lilly
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA

Table Information

Report AttributeDetails
No. of Pages155
PublishedJuly 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 33.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 52.6 Billion
Compound Annual Growth Rate9.6%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Inflammatory Bowel Syndrome Treatment Market - Forecasts from 2023 to 2028 - Product Image

Inflammatory Bowel Syndrome Treatment Market - Forecasts from 2023 to 2028

  • Report
  • 140 Pages
  • Global
From
Japan Gastrointestinal Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F - Product Image

Japan Gastrointestinal Drugs Market, By Region, Competition, Forecast and Opportunities, 2020-2030F

  • Report
  • 80 Pages
  • Japan
From
Gastrointestinal Therapeutics - Global Strategic Business Report - Product Image

Gastrointestinal Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Constipation Treatment Market Report 2025 - Product Image

Constipation Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report - Product Image

Inflammatory Bowel Disease (IBD) Therapeutics - Global Strategic Business Report

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.